Annual revenue fell from KRW 479.7 billion in 2022 to KRW 90.1 billion in 2023, a decline of 81.2%, and the company posted an operating loss of KRW 47 billion in 2023. Revenue recovered to KRW 102.8 billion in 2024, up 14.1%, and operating profit turned to KRW 12.2 billion.
In 2025 revenue reached KRW 118.3 billion, up 15.1%, and operating profit rose to KRW 16.7 billion, up 36.8%, extending the increase to two consecutive years. The operating margin moved from 61.6% in 2022 to -52.2% in 2023, then recovered to 11.9% in 2024 and 14.1% in 2025.
The 2022 result was driven largely by the bio contents unit, which had COVID diagnostics-related revenue, according to a February 2024 research report. The company attributed the 2023 revenue decline to weak results after the COVID endemic transition.
The company said 2024 revenue, excluding the pandemic period, exceeded KRW 100 billion for the first time since its founding. It attributed the 2025 operating profit increase to new product launches, higher sales of existing products and better cost of sales.
Attributable net loss and net loss were both KRW 87.5 billion in 2025, and the company cited losses from equity-method affiliates among the factors behind the swing into loss.
Quarterly figures show a wide gap between operating profit and net income: in Q1 2026 operating profit was KRW 6.35 billion while attributable net income was KRW 41.3 billion, in Q2 operating profit was KRW 8.46 billion against attributable net income of KRW 9.07 billion, and in Q3 operating profit was KRW 7.99 billion against an attributable net loss of KRW 65.3 billion.
Pre-tax loss in Q3 2026 was KRW 75.39 billion, which means non-operating losses far exceeded operating profit. Cumulative January to September 2026 revenue was KRW 101.0 billion, up 11.8%, and operating profit was KRW 22.79 billion, up 43.6%, according to press coverage of the third-quarter report. Operating cash flow fell from KRW 57.9 billion in 2024 to KRW 14.4 billion in 2025.